Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F] fallypride

Neuropsychopharmacology

Volumn 33, Issue 13, 2008, Pages 3111-3125

  Kegeles, Lawrence S ^a,b,d   Slifstein, Mark ^a   Frankle, W Gordon ^a   Xu, Xiaoyan ^a   Hackett, Elizabeth ^a   Bae, Sung A ^a   Gonzales, Robyn ^a   Kim, Jong Hoon ^a   Alvarez, Beatriz ^a   Gil, Roberto ^a   Laruelle, Marc ^a,c   Abi Dargham, Anissa ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b GlaxoSmithKline ^*  (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

18F fallypride; Aripiprazole; Dopamine; PET; Receptor occupancy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FALLYPRIDE F 18; PROLACTIN; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AKATHISIA; ARTICLE; BRAIN CORTEX; BRAIN REGION; CLINICAL ARTICLE; CORPUS STRIATUM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; NEUROMODULATION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BINDING, COMPETITIVE; BRAIN; BRAIN CHEMISTRY; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PIPERAZINES; PITUITARY GLAND; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; QUINOLONES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; YOUNG ADULT;

EID: 57349125689     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.33     Document Type: Article

References (55)

1. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109.
2. Abi-Dargham A, Simpson N, Kegeles L, Parsey R, Hwang D-R, Anjilvel S et al (1999). PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32: 93-109.
3. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB et al (2007). Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response - a double-blind PET study in schizophrenia. Neuropsychopharmacology 32: 1209-1215.
4. Bergstrom M, Muhr C, Lundberg PO, Langstrom B (1991). PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 32: 610-615.
5. Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C et al (1999). In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study. Br J Psychiatry 175: 231-238.
6. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H et al (1997). Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38: 1614-1623.
7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302: 381-389.
8. Deutch AY (1992). The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36: 61-89.
9. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, 4th edn, Text Revision (2000). American Psychiatric Association: Washington, DC.
10. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992). Positron emission tomography analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49: 538-544.
11. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J et al (1997). A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berlin) 133: 396-404.
12. Farde L, Wiesel FA, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71-76.
13. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frakowiak RSJ (1995). Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapping 2: 189-210.
14. Garris PA, Collins LB, Jones SR, Wightman RM (1993). Evoked extracellular dopamine in vivo in the medial prefrontal cortex. J Neurochem 61: 637-647.
15. Grunder G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T et al (2006). The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31: 1027-1035.
16. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
17. Inoue A, Seto M, Sugita S, Hide I, Hirose T, Koga N et al (1998). Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary. Brain Res Mol Brain Res 55: 285-292.
18. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R et al (2007). In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 21: 620-627.
19. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry 157: 514-520.
20. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156: 286-293.
21. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schiz Bull 13: 261-276.
22. Kenakin T (1995). Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16: 232-238.
23. Kenakin T (2007). Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72: 1393-1401.
24. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M et al (2007). A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 22: 433-443.
25. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B et al (2005). Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30: 2283-2289.
26. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B et al (2006). Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31: 1991-2001.
27. Kessler RM (2007). Aripiprazole: what is the role of dopamine D(2) receptor partial agonism? Am J Psychiatry 164: 1310-1312.
28. Kessler RM, Mason N, Jones C, Ansari MS, Manning RF, Price RR (2000). [18F]N-allyl-5-fluoropropylepidepride (fallypride): radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. NeuroImage 11: S32.
29. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y et al (1995). 7-(4-[4-(2, 3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329-336.
30. Lahti RA, Roberts RC, Tamminga CA (1995). D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 6: 2505-2512.
31. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4: 153-158.
32. Laruelle M, Slifstein M, Huang Y (2003). Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5: 363-375.
33. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627.
34. Mailman RB (2007). GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28: 390-396.
35. Mallikaarjun S, Salazar DE, Bramer SL (2004). Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44: 179-187.
36. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 164: 1411-1417.
37. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285-300.
38. Mukherjee J, Yang ZY, Das MK, Brown T (1995). Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3- [18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22: 283-296.
39. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C et al (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33: 227-235.
40. Nyberg S, Dencker SJ, Malm U, Dahl ML, Svenson JO, Halldin C et al (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. Int J Neuropsychopharmacol 1: 95-101.
41. Olsson H, Farde L (2001). Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. Neuroimage 14: 936-945.
42. Ozdemir V, Fourie J, Ozdener F (2002). Aripiprazole (Otsuka Pharmaceutical Co). Curr Opin Investig Drugs 3: 113-120.
43. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997). Limbic selectivity of clozapine. Lancet 350: 490-491.
44. Rieck RW, Ansari MS, Whetsell Jr WO, Deutch AY, Kessler RM (2004). Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology 29: 362-372.
45. Robertson GS, Matsumura H, Fibiger HC (1994). Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271: 1058-1066.
46. Samama P, Cotecchia S, Costa T, Lefkowitz RJ (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625-4636.
47. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74: 1-58.
48. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
49. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH et al (2007). Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebocontrolled trial. Am J Psychiatry 164: 1404-1410.
50. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001). No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 158: 926-930.
51. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H et al (2007a). Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1-13.
52. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007b). Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32: 67-77.
53. Woods RP, Mazziotta JC, Cherry SR (1993). MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17: 536-546.
54. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C et al (2001). In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21: 207-214.
55. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF et al (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27: 248-259.